Proactive Investors - Run By Investors For Investors

Shield Therapeutics' shares rise as it hails results of extended trial of Feraccru

The extended 52-week open-label trial showed increased haemoglobin levels
Feraccru is said to offer a well-tolerated and effective treatment option which can benefit patients over the long term

Shield Therapeutics PLC’s (LON:STX) saw its shares rise on Tuesday as the group said its iron deficiency treatment Feraccru delivered strong benefits for people with kidney-related anaemia in an extended trial.

The extended 52-week open-label study showed increased haemoglobin levels in both those taking it for the whole period and also in those who switched from the placebo after the first 16-weeks.

READ: Shield Therapeutics funded through to 2020

Carl Sterritt, Shield’s chief executive, said: "Such positive long-term treatment data for Feraccru in complex patients with chronic diseases like CKD provides a very promising signal for the future commercial success of Feraccru. 

“Having previously seen similar positive long-term effects in IBD patients with IDA this further clinical trial data provides additional evidence that Feraccru is well-tolerated by a majority of treated patients and is effective at correcting IDA.”

Feraccru is already approved for iron deficiency in adults and in Switzerland for the treatment of iron deficiency anaemia (IDA) in adults with inflammatory bowel disease (IBD).

In October, Shield submitted Feraccru to the US Food and Drug Administration for approval as a treatment for iron deficiency.

Well-tolerated and effective treatment option

Dr Mark Sampson, Shield’s chief medical officer, added:  "Iron deficiency is a significant and progressive issue in patients with chronic renal disease which has been challenging to treat due to poor compliance with traditional oral iron salts. 

“These results suggest that Feraccru offers a well-tolerated and effective treatment option which can benefit patients over the long-term."

As confirming it is well-tolerated, the extended trial demonstrated chronic treatment with Feraccru can maintain Hb (haemoglobin) levels in a number of conditions that cause iron deficiency. 

“As previously shown in patients with IDA associated with IBD, this study in CKD patients demonstrates that Feraccru is also well tolerated in a group of patients whose IDA is caused by a very different primary disease,” said the statement.

Shares jump, Liberum repeats 'buy'

In late morning trading, shares in Shield Therapeutics were 10.9% higher at 47.00p.

In a note to clients, analysts at Liberum Capital reiterated a ‘buy’ rating and an 80p per share price target on Shield Therapeutics.

The City broker’s analyst said: “This data further validates the potential for Feraccru in CKD and should help to convince prescribers of the longer-term benefits of the drug. The key event remains the US FDA approval decision due by the end of July this year.”

 -- Adds share price, analyst comment --

View full STX profile View Profile

Shield Therapeutics PLC Timeline

Related Articles

human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use